In regards to the biotech sector, the author of today’s article advises that “it makes sense to keep an eye on this general area of the market as it is likely to play an increasingly significant role not just in the fight against Covid-19 but also in the war on cancer, the battle against rare diseases, and increasingly on more common diseases where traditional treatments are running into limitations.” For what he sees as an ideal way to invest in biotech – and his recommendation on when to buy – CLICK HERE.
Clinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only are analysts bullish on but which are trading for less than $5 a share and boast upside potential of over 100%. For more, CLICK HERE.
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.
“Biotech penny stocks have always been a big focus for investors but this year has been one of the most active years for the sector,” observes the author of today’s article. And while the coronavirus outbreak has been a major reason for this increased activity, the author notes that “you also have companies hitting big milestones for other health indications.” With this being perhaps one of the best times to bet on biotech penny stocks, the author highlights four in particular to have a look at. For more, CLICK HERE.
When it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors are likely to end up disappointed. For more, CLICK HERE.
“The tech sector is once again outperforming the overall market in 2020 as investors continue to go all-in on growth,” observes the author of today’s article. However, the tech giants that have led the market’s rise may have limited upside left in the near term, and tech investors may be better off focusing on small-cap tech stocks. For seven high-quality small-cap tech stocks identified as top picks by Bank of America, CLICK HERE.
“Understandably, investors have taken a more cautious approach when navigating the confused financial environment, but focus is locking in on the biotech sector as it has been able to withstand the COVID-19-induced pressure on the market,” notes the author of today’s article. She proceeds to highlight three “Strong Buy”-rated biotech stocks trading for less than $5 a share that, with upside potential in the 500% to 700% range based on analyst price targets, possess “explosive upside potential.” For more, CLICK HERE.
The “sleeper” biotech highlighted in today’s article, a company with a unique name and focused on therapies for very rare, pediatric cancers, has a promising pipeline – including two drugs that could be approved in the next year. This, combined with the fact that its stock price has steadily increased since its IPO (despite getting caught up in the coronavirus market sell-off), leads the author to recommend investors keep this company on their radars for potential buy the dip opportunities. For the biotech stock in question, CLICK HERE.
It’s the most popular investing theme this year: COVID-19 vaccine producers. However, the recent reversal of fortunes for the stock of one biotech firm – whose stock had nearly tripled since the beginning of March when the firm announced it was working on a vaccine for the novel coronavirus – illustrates the risk involved with “chasing vaccine hype”. For more, CLICK HERE.
Cannabis investors who bet that marijuana stocks would benefit from an increase in demand for cannabis products during the coronavirus lockdowns have largely been disappointed. As today’s article notes, even if demand for marijuana did rise with people stuck at home, “it hasn’t translated to gains for major cannabis producers.” Is more disappointment ahead from marijuana stocks? For more, CLICK HERE.